» Articles » PMID: 39728178

Targeting Reactive Oxygen Species for Diagnosis of Various Diseases

Overview
Date 2024 Dec 27
PMID 39728178
Authors
Affiliations
Soon will be listed here.
Abstract

Reactive oxygen species (ROS) are generated predominantly during cellular respiration and play a significant role in signaling within the cell and between cells. However, excessive accumulation of ROS can lead to cellular dysfunction, disease progression, and apoptosis that can lead to organ dysfunction. To overcome the short half-life of ROS and the relatively small amount produced, various imaging methods have been developed, using both endogenous and exogenous means to monitor ROS in disease settings. In this review, we discuss the molecular mechanisms underlying ROS production and explore the methods and materials that could be used to detect ROS overproduction, including iron-based materials, ROS-responsive chemical bond containing polymers, and ROS-responsive molecule containing biomaterials. We also discuss various imaging and imaging techniques that could be used to target and detect ROS overproduction. We discuss the ROS imaging potentials of established clinical imaging methods, such as magnetic resonance imaging (MRI), sonographic imaging, and fluorescence imaging. ROS imaging potentials of other imaging methods, such as photoacoustic imaging (PAI) and Raman imaging (RI) that are currently in preclinical stage are also discussed. Finally, this paper focuses on various diseases that are associated with ROS overproduction, and the current and the future clinical applications of ROS-targeted imaging. While the most widely used clinical condition is cardiovascular diseases, its potential extends into non-cardiovascular clinical conditions, such as neurovascular, neurodegenerative, and other ROS-associated conditions, such as cancers, skin aging, acute kidney injury, and inflammatory arthritis.

Citing Articles

The interplay of ferroptosis and oxidative stress in the pathogenesis of aortic dissection.

Zhang Z, Wang H, Kan X, Zhang X, Xu S, Cai J Front Pharmacol. 2025; 16:1519273.

PMID: 39974735 PMC: 11835687. DOI: 10.3389/fphar.2025.1519273.

References
1.
Bezold M, Hanna A, Dollinger B, Patil P, Yu F, Duvall C . Hybrid Shear-thinning Hydrogel Integrating Hyaluronic Acid with ROS-Responsive Nanoparticles. Adv Funct Mater. 2023; 33(31). PMC: 10723243. DOI: 10.1002/adfm.202213368. View

2.
Udriste A, Burdusel A, Niculescu A, Radulescu M, Grumezescu A . Metal-Based Nanoparticles for Cardiovascular Diseases. Int J Mol Sci. 2024; 25(2). PMC: 10815551. DOI: 10.3390/ijms25021001. View

3.
Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

4.
Estevez A, Ganesana M, Trentini J, Olson J, Li G, Boateng Y . Antioxidant Enzyme-Mimetic Activity and Neuroprotective Effects of Cerium Oxide Nanoparticles Stabilized with Various Ratios of Citric Acid and EDTA. Biomolecules. 2019; 9(10). PMC: 6843313. DOI: 10.3390/biom9100562. View

5.
Han D, Wang F, Shen D . Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury. Theranostics. 2024; 14(13):5336-5370. PMC: 11388064. DOI: 10.7150/thno.99961. View